Am Fam Physician. 2007 May 1;75(9):1304.
to the editor: The STEPS article on exenatide injection (Byetta) concluded that it is an inconvenient drug with no proven benefits over other drugs for the management of diabetes.1 However, the authors did not discuss the weight loss benefit of exenatide in patients with diabetes who are obese.
In a clinical trial of patients with diabetes who were receiving metformin (Glucophage), the addition of exenatide was associated with progressive weight loss in obese and nonobese patients in a dose-dependent manner compared with placebo.2 When used appropriately as add-on therapy, exenatide has an advantage over sulfonylureas and insulin because it does not increase the risk of hypoglycemia.
As medical director of a bariatric practice, I have seen greater weight loss in obese patients with type 2 diabetes who were receiving exenatide compared with those taking sulfonylureas, thiazolidinediones, or insulin. I also would argue that exenatide is easier to use than insulin because of its prefilled pen design and simple dosing schedule. Medications like exenatide, which may have a positive impact on the “diabesity” epidemic, warrant additional consideration.
Author disclosure: Nothing to disclose.
1. Ezzo DC, Ambizas EM. Exenatide injection (Byetta): adjunctive therapy for glycemic control. Am Fam Physician. 2006;73:2213–4.
2. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092–100.
editor's note: This letter was sent to the authors of the STEPS article, who declined to reply.
Send letters to email@example.com, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.
Copyright © 2007 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions